Linoserpaturev

N/A

Report date: 2026/04/28 20:00:22
First In Class

Base Information

Drug NameLinoserpaturev
Drug Alias NamerQNestinrQNestin34.5v.2rQNestin34.5CAN-3110
ClassificationBiologics > Oncolytic virusCell and gene therapy > Gene therapy
Mechanisms of ActionCell death stimulantsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsBrain NeoplasmsOligodendrogliomaGanglioglioma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Brigham and Women's HospitalCandel Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteCandel Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsBrain NeoplasmsOligodendrogliomaGanglioglioma +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A